Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Jun 03, 2021 9:36am
81 Views
Post# 33317990

RE:RE:RE:RE:RE:No trades

RE:RE:RE:RE:RE:No tradesLT - I completely disagree that it is arrogant.  And any company that retaliates against shareholders for providing great guidance is foolish and doomed to fail anyway.  Plus, it would only hurt the value of the shares they own, and that would be even more foolish.  If I see any evidence of that kind of prideful arrogance on the company's part, I'll sell all my shares immediately and walk away, while waiting on a class action lawsuit.  The scorecard has the correct measurements, and those are all items that should become publically visible.  That's the whole point of focusing on this critical issue.  There is no visibility for the majority of the market, and THTX simply has to do a better job for that amazing story to be received.  I don't thank SPCEO or anyone else dismisses the fact that lots of things are likely happening behind the scenes.  But those things can easily be graded on a timeline of how well the company is doing at promoting themselves and gaining traction in the market.  
<< Previous
Bullboard Posts
Next >>